The panel meeting is 5/23/12; the PDUFA date is in late June. Note that JNJ has submitted a separate Xarelto NDA for the (partially overlapping) indication of PCI secondary to ACS (#msg-75391993).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.